Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Macdonald

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
British Journal of Cancer|March 4, 2023
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumoursMelissa L Johnson, Judy S Wang, Gerald Falchook, et al.
British Journal of Clinical Pharmacology|December 20, 2018
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patientsGeorgios Vlasakakis, Antonella Napolitano, Ruth Barnard, et al.
Chemical Communications (Cambridge, England)|March 17, 2021
An electrochemical SARS-CoV-2 biosensor inspired by glucose test strip manufacturing processesVincent J Vezza, Adrian Butterworth, Perrine Lasserre, et al.
Analytical Chemistry|January 19, 2022
SARS-CoV-2 Aptasensors Based on Electrochemical Impedance Spectroscopy and Low-Cost Gold Electrode SubstratesPerrine Lasserre, Banushan Balansethupathy, Vincent J Vezza, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast CancerJohn F R Robertson, Abigail Evans, Stephan Henschen, et al.
Nature Biomedical Engineering|January 29, 2020
On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiologyDavid B Chou, Viktoras Frismantas, Yuka Milton, et al.
Nature Biomedical Engineering|February 14, 2020
Author Correction: On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiologyDavid B Chou, Viktoras Frismantas, Yuka Milton, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
British Journal of Cancer|March 4, 2023
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumoursMelissa L Johnson, Judy S Wang, Gerald Falchook, et al.
British Journal of Clinical Pharmacology|December 20, 2018
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patientsGeorgios Vlasakakis, Antonella Napolitano, Ruth Barnard, et al.
Chemical Communications (Cambridge, England)|March 17, 2021
An electrochemical SARS-CoV-2 biosensor inspired by glucose test strip manufacturing processesVincent J Vezza, Adrian Butterworth, Perrine Lasserre, et al.
Analytical Chemistry|January 19, 2022
SARS-CoV-2 Aptasensors Based on Electrochemical Impedance Spectroscopy and Low-Cost Gold Electrode SubstratesPerrine Lasserre, Banushan Balansethupathy, Vincent J Vezza, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast CancerJohn F R Robertson, Abigail Evans, Stephan Henschen, et al.
Nature Biomedical Engineering|January 29, 2020
On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiologyDavid B Chou, Viktoras Frismantas, Yuka Milton, et al.
Nature Biomedical Engineering|February 14, 2020
Author Correction: On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiologyDavid B Chou, Viktoras Frismantas, Yuka Milton, et al.
Pageof 4